(firstQuint)Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma.

 A non-randomised, open label, single-arm phase II study to evaluate the efficacy and safety of 1st-line pazopanib followed by 2nd-line everolimus in patients with previously untreated advanced or metastatic renal cell carcinoma.

 Subjects will receive initial therapy with pazopanib, followed, on progression, by 2nd-line therapy with everolimus.

 Study treatment, sequential treatment with pazopanib followed by everolimus, will continue until disease progression, unacceptable toxicity, withdrawal of consent or death.

.

 Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma@highlight

Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma